Advanced

Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy

Thirion, P; Holmberg, Ola LU ; Collins, CD; O'Shea, C; Moriarty, M; Pomeroy, M; O'Sullivan, C; Buckney, S and Armstrong, J (2004) In Radiotherapy and Oncology 71(2). p.163-166
Abstract
Background and Purpose: To prospectively assess the feasibility and efficacy of a hypofractionated accelerated radiotherapy regimen (72 Gy in 24 daily fractions, 3Gy per fraction) in patients (pts) with non-resectable non-small-cell lung cancer (NSCLC). Material and Methods: We included 25 Ins with a histologically or cytologically proven NSCLC, with KPS greater than or equal to 70 and less than or equal to 10% weight loss over prior three months, and with tumour stage I/II medically inoperable (9 pts) or non-resectable stage III a/b without pleural effusion (16 pts). Eleven pts received induction chemotherapy. No more than 30% of the combined lung volume could receive more than 25 Gy and the maximal biological effective dose to the spinal... (More)
Background and Purpose: To prospectively assess the feasibility and efficacy of a hypofractionated accelerated radiotherapy regimen (72 Gy in 24 daily fractions, 3Gy per fraction) in patients (pts) with non-resectable non-small-cell lung cancer (NSCLC). Material and Methods: We included 25 Ins with a histologically or cytologically proven NSCLC, with KPS greater than or equal to 70 and less than or equal to 10% weight loss over prior three months, and with tumour stage I/II medically inoperable (9 pts) or non-resectable stage III a/b without pleural effusion (16 pts). Eleven pts received induction chemotherapy. No more than 30% of the combined lung volume could receive more than 25 Gy and the maximal biological effective dose to the spinal cord was maintained below 44 Gy. Results: No grade-4 acute toxicity event was reported. Two pts had a treatment break because of grade-3 acute oesophagitis. Twenty-two pts were evaluable for long-term toxicity (median follow-up = 9.7 months, range 4 to 30.2 months). There were 4 Grade-1 pulmonary and 2 Grade-1 oesophageal long-term toxicity events. Twenty-two pts were evaluable for tumour response with 7 complete and 8 partial responses, 5 stable diseases and 2 progressive diseases. The actuarial 1-year overall and thoracic-progression-free survival rates were 68% and 72% respectively. Conclusions: This study demonstrates the feasibility of the experimental radiotherapy schedule, however more data are needed to confirm its efficacy. (C) 2003 Published by Elsevier Ireland Ltd. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
non-small-cell lung cancer, three-dimensional conformal radiation, therapy, acceleration, dose escalation, hypofractionation
in
Radiotherapy and Oncology
volume
71
issue
2
pages
163 - 166
publisher
Elsevier
external identifiers
  • wos:000221371300006
  • pmid:15110449
  • scopus:1942542250
ISSN
1879-0887
DOI
10.1016/j.radonc.2003.09.006
language
English
LU publication?
yes
id
d71b1675-3fb9-421b-b010-9a59c6491625 (old id 898995)
date added to LUP
2008-01-18 14:05:55
date last changed
2017-02-12 03:40:00
@article{d71b1675-3fb9-421b-b010-9a59c6491625,
  abstract     = {Background and Purpose: To prospectively assess the feasibility and efficacy of a hypofractionated accelerated radiotherapy regimen (72 Gy in 24 daily fractions, 3Gy per fraction) in patients (pts) with non-resectable non-small-cell lung cancer (NSCLC). Material and Methods: We included 25 Ins with a histologically or cytologically proven NSCLC, with KPS greater than or equal to 70 and less than or equal to 10% weight loss over prior three months, and with tumour stage I/II medically inoperable (9 pts) or non-resectable stage III a/b without pleural effusion (16 pts). Eleven pts received induction chemotherapy. No more than 30% of the combined lung volume could receive more than 25 Gy and the maximal biological effective dose to the spinal cord was maintained below 44 Gy. Results: No grade-4 acute toxicity event was reported. Two pts had a treatment break because of grade-3 acute oesophagitis. Twenty-two pts were evaluable for long-term toxicity (median follow-up = 9.7 months, range 4 to 30.2 months). There were 4 Grade-1 pulmonary and 2 Grade-1 oesophageal long-term toxicity events. Twenty-two pts were evaluable for tumour response with 7 complete and 8 partial responses, 5 stable diseases and 2 progressive diseases. The actuarial 1-year overall and thoracic-progression-free survival rates were 68% and 72% respectively. Conclusions: This study demonstrates the feasibility of the experimental radiotherapy schedule, however more data are needed to confirm its efficacy. (C) 2003 Published by Elsevier Ireland Ltd.},
  author       = {Thirion, P and Holmberg, Ola and Collins, CD and O'Shea, C and Moriarty, M and Pomeroy, M and O'Sullivan, C and Buckney, S and Armstrong, J},
  issn         = {1879-0887},
  keyword      = {non-small-cell lung cancer,three-dimensional conformal radiation,therapy,acceleration,dose escalation,hypofractionation},
  language     = {eng},
  number       = {2},
  pages        = {163--166},
  publisher    = {Elsevier},
  series       = {Radiotherapy and Oncology},
  title        = {Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy},
  url          = {http://dx.doi.org/10.1016/j.radonc.2003.09.006},
  volume       = {71},
  year         = {2004},
}